A detailed history of Man Group PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Man Group PLC holds 7,655 shares of PTGX stock, worth $364,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,655
Holding current value
$364,531
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $188,772 - $266,394
7,655 New
7,655 $265,000
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $104,033 - $157,887
14,135 Added 17.68%
94,070 $1.03 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $496,233 - $739,299
63,134 Added 375.78%
79,935 $674,000
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $118,615 - $428,761
16,801 New
16,801 $133,000
Q3 2018

Nov 14, 2018

SELL
$6.82 - $11.26 $587,379 - $969,778
-86,126 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$5.99 - $9.1 $515,894 - $783,746
86,126 New
86,126 $579,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.